Any proposed treatment without any proof it will ever work can get ODD for an "orphan" disease (e.g. limited population, and profit potential). Big Whoop.
No such CTs exist. Just a couple of ad hoc studies from 1999 never sanctioned by the FDA. And they were flawed. Not to mention now 20 yrs behind better current treatments.
And that's why he never mentions the farcical CIAB as an emerging treatment in his conference presentations? Hidalgo got a little carried away before collecting his advisory paycheck a few yrs back.
So what. BMY's oncology focus is not on 20 yr old chemo treatments. And that includes the "Kenny Wonder Treatment". Instead they are into immuno, and targeted pathway drugs. Drugs like Odipo a PD-1 inhibitor. Which ties into Hidalgo's recent work with BL-8040+Keytruda. Oh gee wizz golly Keytruda is a PD-1 inhibitor, and we have a match.
Neither should SHs be surprised if Hidalgo walks away from PMCB. He has other more high paying gigs rolling in (e.g. Genechem 08-Apr-21) . Able to afford to pay him a higher rate.
Outside of one Kenny PR pump, now years ago, he feels sooooo good about the Kenny Wonder Treatment that he never gives any presentations on it.
Which is an impossibility. For every buy there is a sell. And the trend recently has been downward in PPS. With retail waiting on the next Kenny PR pump. Most likely fueled by speculation coming out of the 16-Jun SH meeting.